Consensus Biogen Inc.

Stocks

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 11/09/2026 BST			5-day change	1st Jan Change
217.15 ^USD	+0.80%		-1.67%	+23.39%

09-11	Scholar Rock gets first FDA nod for rare muscle-wasting disease	RE
09-11	US FDA approves Scholar Rock's muscle weakness drug	RE

Evolution of the Average Target: Biogen Inc.

Evolution of the Target Price: Biogen Inc.

Changes in Analyst Recommendations: Biogen Inc.

2866b9446b60f74df7db063.VkNtFoh7uFRuMV96fN2QO4L9k2_W4UpPg8W_Az5kIRk.AQ5abMcL3zk_XS8UNYf7ddKQ1Vywrzg5tfSMQXUjVVwbOlpg-TzNYzx3Bg~29a1217ee4f88cb9057f8f7f767d6fd1

Analysts' recommendations: Biogen Inc.

09-03	Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240, Keeps Outperform Rating	MT
08-25	RBC Adjusts Price Target on Biogen to $260 From $240, Maintains Outperform Rating	MT
08-25	RBC Capital Adjusts Price Target on Biogen to $260 From $240	MT
08-13	Wolfe Upgrades Biogen to Outperform From Peer Perform, Price Target is $300	MT
08-10	HSBC Adjusts Price Target on Biogen to $165 From $157, Keeps Reduce Rating	MT
08-03	Mizuho Adjusts Price Target on Biogen to $241 From $221	MT
07-30	BMO Capital Adjusts Price Target on Biogen to $208 From $196, Maintains Market Perform Rating	MT
07-30	TD Cowen Adjusts Price Target on Biogen to $225 From $215, Maintains Buy Rating	MT
07-30	Canaccord Genuity Adjusts Price Target on Biogen to $248 From $245, Maintains Buy Rating	MT
07-30	Goldman Sachs Adjusts Price Target on Biogen to $290 From $271, Maintains Buy Rating	MT
07-30	BMO Raises Price Target on Biogen to $208 From $196, Keeps Market Perform Rating	MT
07-30	UBS Adjusts Price Target on Biogen to $240 From $225, Maintains Buy Rating	MT
07-30	RBC Trims Price Target on Biogen to $240 From $242, Keeps Outperform Rating	MT
07-29	JPMorgan Lifts Biogen Price Target to $210 From $185	MT
07-29	Wedbush Adjusts Biogen Price Target to $215 From $201, Maintains Neutral Rating	MT
07-29	Stifel Nicolaus Adjusts Biogen Price Target to $242 From $214	MT
07-28	Barclays Adjusts Biogen Price Target to $200 From $185, Maintains Equalweight Rating	MT
07-24	Rothschild & Co Redburn Adjusts Price Target on Biogen to $210 From $190, Maintains Neutral Rating	MT
07-21	BofA Securities Adjusts Biogen Price Target to $215 From $217	MT
07-21	Guggenheim Adjusts Price Target on Biogen to $280 From $260, Maintains Buy Rating	MT
07-20	Goldman Sachs Adjusts Price Target on Biogen to $271 From $250, Maintains Buy Rating	MT
07-14	Cantor Fitzgerald Adjusts Biogen Price Target to $237 From $206	MT
07-13	Wedbush Raises Price Target on Biogen to $201 From $196, Keeps Neutral Rating	MT
07-13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	BIOGEN INC.					+9.23%
	REGENERON PHARMACEUTICALS, INC.					+8.68%
	CSL LIMITED					+2.83%
	MODERNA, INC.					-16.96%
	SAMSUNG BIOLOGICS CO.,LTD.					+39.05%
	UCB					+38.62%
	INCYTE CORPORATION					+5.16%
	INNOVENT BIOLOGICS, INC.					+37.46%
	SWEDISH ORPHAN BIOVITRUM AB					+14.26%
	ALTEOGEN INC.					+47.24%
	Average					+18.56%
	Weighted average by Cap.					+14.23%